Regulatory News:

BIOCORP (FR0012788065 – ALCOR / Eligible PEA‐PME) (Paris:ALCOR), a French company specialized in the design, development, and manufacturing of innovative medical devices, presents its financial reporting schedule for 2023(1).



2022 full-year results


Thursday, April 6th, 2023

Before the market opening


Annual shareholders meeting


Tuesday, May 16th, 2023


2023 first-half results


Thursday, September 28th, 2023

Before the market opening


(1) This schedule is indicative and subject to change.


Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has today acquired a leading position in the connected medical device market thanks to Mallya. This smart sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of patients with diabetes. Available for sale from 2020, Mallya spearheads BIOCORP's product portfolio of innovative connected solutions. The company has 80 employees. BIOCORP is listed on Euronext since July 2015 (FR0012788065 – ALCOR).

For more information, please visit

BIOCORP Jacques Gardette Chairman of the Board

Éric Dessertenne Chief Executive Officer

Sylvaine Dessard Marketing & Communication Director + 33 (0)6 88 69 72 85

ULYSSE COMMUNICATION Bruno ARABIAN +33 (0)6 87 88 47 26

Margaux Puech +33 (0)7 86 16 01 09

Biocorp (EU:ALCOR)
Historical Stock Chart
From May 2023 to Jun 2023 Click Here for more Biocorp Charts.
Biocorp (EU:ALCOR)
Historical Stock Chart
From Jun 2022 to Jun 2023 Click Here for more Biocorp Charts.